Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.

Check Now !

Critical Limb Ischemia Pipeline Insight

DelveInsight’s, “Critical Limb Ischemia - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Critical Limb Ischemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Critical Limb Ischemia Understanding

Critical Limb Ischemia: Overview

Critical Limb Ischemia (CLI) is a chronic condition and the most serious form of peripheral arterial disease (PAD). It is a major global health problem with a high and growing incidence. Importantly CLI has currently, limited treatment options and has a severe impact on the patient’s quality of life. CLI results from a severe blockage of the arteries in the lower limbs Symptoms include severe burning pain in the feet or toes even at rest. Complications include ulcers in the legs and feet that do not heal and commonly lead to gangrene and for which amputation of the affected limb is the only treatment option. The global amputation rate is estimated at 25% within one year of diagnosis, but vary according to the severity of the condition with rates of 11% in patients with superficial ulcers and up to 83% in patients with gangrene. In addition to limb loss, CLI is associated with a high risk of cardiovascular events, including myocardial infarction, stroke and death. The mortality risk has been reported to be as high as 20-25% within one year of diagnosis and surpasses 50% at 5 years post-diagnosis.


"Critical Limb Ischemia - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Critical Limb Ischemia pipeline landscape is provided which includes the disease overview and Critical Limb Ischemia treatment guidelines. The assessment part of the report embraces, in depth Critical Limb Ischemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Critical Limb Ischemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Critical Limb Ischemia R&D. The therapies under development are focused on novel approaches to treat/improve Critical Limb Ischemia.

Critical Limb Ischemia Emerging Drugs Chapters

This segment of the Critical Limb Ischemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Critical Limb Ischemia Emerging Drugs


Emiplacel: Pluristem Therapeutics

Emiplacel is a human placental stromal cell therapy being developed by Pluristem Therapeutics (formerly Pluristem Life Systems) by using its proprietary. Currently, it is in Phase III stage of clinical trial evaluation to treat Critical Limb Ischemia.


RJX: Reven Pharmaceuticals

RJX is an intravenous (IV) drug technology platform formulated to provide multimodal support to cells. The platform approach enables the company to customize treatment dosage and frequency according to different therapeutic interests. The RJX platform technology is designed to target areas of metabolic function, oxidative stress, and blood vessel control among others. In layman's terms, the company believe RJX can mimic various physiological aspects of physical exercise and in doing so, modulate the microenvironment in which cells interact with our bloodstream and ultimately affect the microenvironment within cells themselves. Nutrient, antioxidant, and electrolyte components in RJX are also expected to contribute to this “micro-environment modulation” effect. Thus, each dose of RJX is believed to present an opportunity to condition cells towards wellness.

Further product details are provided in the report……..

Critical Limb Ischemia: Therapeutic Assessment

This segment of the report provides insights about the different Critical Limb Ischemia drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Critical Limb Ischemia

There are approx. 20+ key companies which are developing the therapies for Critical Limb Ischemia. The companies which have their Critical Limb Ischemia drug candidates in the most advanced stage, i.e. phase III include, Pluristem Therapeutics.

Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Critical Limb Ischemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Critical Limb Ischemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Critical Limb Ischemia therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Critical Limb Ischemia drugs.

Critical Limb Ischemia Report Insights

  • Critical Limb Ischemia Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Critical Limb Ischemia Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Critical Limb Ischemia drugs?
  • How many Critical Limb Ischemia drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Critical Limb Ischemia?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Critical Limb Ischemia therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Critical Limb Ischemia and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Critical Limb Ischemia: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Critical Limb Ischemia – DelveInsight’s Analytical Perspective

Late Stage Products (Phase III)

  • Comparative Analysis

Emiplacel: Pluristem Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

CLBS12: Caladrius Biosciences

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

RJX: Reven Pharmaceuticals

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Critical Limb Ischemia Key Companies

Critical Limb Ischemia Key Products

Critical Limb Ischemia- Unmet Needs

Critical Limb Ischemia- Market Drivers and Barriers

Critical Limb Ischemia- Future Perspectives and Conclusion

Critical Limb Ischemia Analyst Views

Critical Limb Ischemia Key Companies

Appendix

List of Table

Table 1: Total Products for Critical Limb Ischemia

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Critical Limb Ischemia

Figure 2: Late Stage Products                             

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products

• Pluristem Therapeutics

• Reven Pharmaceuticals, Inc.

• New Beta Innovation Limited

• Libella Gene Therapeutics

• Lifecells, LLC.

• Helixmith

• Caladrius Biosciences, Inc.

• Beijing Northland Biotech. Co., Ltd.

• BioGenCell Ltd.

• Ixaka Ltd

• Anaeropharma Science

• Antidote Therapeutics

• Cynata Therapeutics Limited

• Gurus BioPharm LLC

• Hemostemix Inc.

• Juventas Therapeutics

• Rexgenero

• Symic Bio

• Ambulero, Inc.

Forward to Friend

Need A Quote